Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
0.190
+0.027 (16.78%)
Nov 20, 2024, 4:00 PM EST - Market open
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $2.82M in the quarter ending September 30, 2024, a decrease of -29.26%. This brings the company's revenue in the last twelve months to $11.29M, up 183.05% year-over-year. In the year 2023, Tonix Pharmaceuticals Holding had annual revenue of $7.77M.
Revenue (ttm)
$11.29M
Revenue Growth
+183.05%
P/S Ratio
0.30
Revenue / Employee
$109,621
Employees
103
Market Cap
34.84M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
FibroGen | 180.02M |
Precision Optics Corporation | 18.98M |
Co-Diagnostics | 7.32M |
Moolec Science | 5.63M |
HCW Biologics | 3.50M |
Beyond Air | 2.34M |
TNXP News
- 6 hours ago - Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Research Report 2024: Comprehensive Insights on 8+ Drugs Featuring Tonix Pharmaceuticals, BMS, WinSanTor, and Apnimed - GlobeNewsWire
- 2 days ago - Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual - GlobeNewsWire
- 7 days ago - Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments - Accesswire
- 7 days ago - Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting - GlobeNewsWire
- 8 days ago - Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals - GlobeNewsWire
- 20 days ago - Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 - GlobeNewsWire
- 23 days ago - Tonix Pharmaceuticals to Present at BIO-Europe® 2024 - GlobeNewsWire
- 27 days ago - Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference - GlobeNewsWire